A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2027-05-04
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to verify the clinical benefit of monthly doses of
aducanumab in slowing cognitive and functional impairment as measured by changes in the
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in
participants with early Alzheimer's disease.